Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

T. Meyer; R. Finn; M. Kudo; Y. Kang; C. Yen; P. Galle; J. Llovet; E. Assenat; G. Brandi; K. Motomura; T. Okusaka; R. Hubner; M. Karwal; A. Baron; M. Ikeda; K. Liang; C. Wang; R. Widau; W. Schelman; A. Zhu

doi:10.1093/annonc/mdz154.020

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

T. Meyer, R. Finn, M. Kudo, Y. Kang, C. Yen, P. Galle, J. Llovet, E. Assenat, G. Brandi, K. Motomura, T. Okusaka, R. Hubner, M. Karwal, A. Baron, M. Ikeda, K. Liang, C. Wang, R. Widau, W. Schelman, A. Zhu

腫瘤科

研究成果: Article › 同行評審

原文	English
頁（從 - 到）	iv133
期刊	Annals of oncology : official journal of the European Society for Medical Oncology
卷	30
DOIs	https://doi.org/10.1093/annonc/mdz154.020
出版狀態	Published - 2019 七月 1

All Science Journal Classification (ASJC) codes

Hematology
Oncology

存取文件

10.1093/annonc/mdz154.020

引用此

Meyer, T., Finn, R., Kudo, M., Kang, Y., Yen, C., Galle, P., Llovet, J., Assenat, E., Brandi, G., Motomura, K., Okusaka, T., Hubner, R., Karwal, M., Baron, A., Ikeda, M., Liang, K., Wang, C., Widau, R., Schelman, W., & Zhu, A. (2019). Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv133. https://doi.org/10.1093/annonc/mdz154.020

Meyer, T. ; Finn, R. ; Kudo, M. ; Kang, Y. ; Yen, C. ; Galle, P. ; Llovet, J. ; Assenat, E. ; Brandi, G. ; Motomura, K. ; Okusaka, T. ; Hubner, R. ; Karwal, M. ; Baron, A. ; Ikeda, M. ; Liang, K. ; Wang, C. ; Widau, R. ; Schelman, W. ; Zhu, A. / Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib : outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). 於: Annals of oncology : official journal of the European Society for Medical Oncology. 2019 ; 卷 30. 頁 iv133.

@article{3517581250db446d9888dc5a4f386128,

title = "Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)",

author = "T. Meyer and R. Finn and M. Kudo and Y. Kang and C. Yen and P. Galle and J. Llovet and E. Assenat and G. Brandi and K. Motomura and T. Okusaka and R. Hubner and M. Karwal and A. Baron and M. Ikeda and K. Liang and C. Wang and R. Widau and W. Schelman and A. Zhu",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz154.020",

language = "English",

volume = "30",

pages = "iv133",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Meyer, T, Finn, R, Kudo, M, Kang, Y, Yen, C, Galle, P, Llovet, J, Assenat, E, Brandi, G, Motomura, K, Okusaka, T, Hubner, R, Karwal, M, Baron, A, Ikeda, M, Liang, K, Wang, C, Widau, R, Schelman, W & Zhu, A 2019, 'Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)', Annals of oncology : official journal of the European Society for Medical Oncology, 卷 30, 頁 iv133. https://doi.org/10.1093/annonc/mdz154.020

Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib : outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). / Meyer, T.; Finn, R.; Kudo, M.; Kang, Y.; Yen, C.; Galle, P.; Llovet, J.; Assenat, E.; Brandi, G.; Motomura, K.; Okusaka, T.; Hubner, R.; Karwal, M.; Baron, A.; Ikeda, M.; Liang, K.; Wang, C.; Widau, R.; Schelman, W.; Zhu, A.

於: Annals of oncology : official journal of the European Society for Medical Oncology, 卷 30, 01.07.2019, p. iv133.

研究成果: Article › 同行評審

TY - JOUR

T1 - Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib

T2 - outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH)

AU - Meyer, T.

AU - Finn, R.

AU - Kudo, M.

AU - Kang, Y.

AU - Yen, C.

AU - Galle, P.

AU - Llovet, J.

AU - Assenat, E.

AU - Brandi, G.

AU - Motomura, K.

AU - Okusaka, T.

AU - Hubner, R.

AU - Karwal, M.

AU - Baron, A.

AU - Ikeda, M.

AU - Liang, K.

AU - Wang, C.

AU - Widau, R.

AU - Schelman, W.

AU - Zhu, A.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85079423446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079423446&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz154.020

DO - 10.1093/annonc/mdz154.020

M3 - Article

C2 - 32085038

VL - 30

SP - iv133

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P 等. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Annals of oncology : official journal of the European Society for Medical Oncology. 2019 7月 1;30:iv133. https://doi.org/10.1093/annonc/mdz154.020